These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1657 related items for PubMed ID: 20811725

  • 1. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
    Li CM, Narayanan R, Lu Y, Hurh E, Coss CC, Barrett CM, Miller DD, Dalton JT.
    Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
    [Abstract] [Full Text] [Related]

  • 2. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Müller M, Langer O, Wacheck V.
    Clin Cancer Res; 2011 Aug 15; 17(16):5322-32. PubMed ID: 21712451
    [Abstract] [Full Text] [Related]

  • 3. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.
    Cancer Res; 2009 Jul 15; 69(14):5835-42. PubMed ID: 19584292
    [Abstract] [Full Text] [Related]

  • 4. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway.
    He L, Wu Y, Lin L, Wang J, Wu Y, Chen Y, Yi Z, Liu M, Pang X.
    Cancer Sci; 2011 Jan 15; 102(1):219-25. PubMed ID: 21087351
    [Abstract] [Full Text] [Related]

  • 5. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2010 Jan 15; 51(1):421-9. PubMed ID: 19661225
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.
    Clin Cancer Res; 2004 Dec 01; 10(23):8059-67. PubMed ID: 15585641
    [Abstract] [Full Text] [Related]

  • 7. Modulation of the activities of AMP-activated protein kinase, protein kinase B, and mammalian target of rapamycin by limiting energy availability with 2-deoxyglucose.
    Jiang W, Zhu Z, Thompson HJ.
    Mol Carcinog; 2008 Aug 01; 47(8):616-28. PubMed ID: 18247380
    [Abstract] [Full Text] [Related]

  • 8. Curcumin dually inhibits both mammalian target of rapamycin and nuclear factor-κB pathways through a crossed phosphatidylinositol 3-kinase/Akt/IκB kinase complex signaling axis in adenoid cystic carcinoma.
    Sun ZJ, Chen G, Zhang W, Hu X, Liu Y, Zhou Q, Zhu LX, Zhao YF.
    Mol Pharmacol; 2011 Jan 01; 79(1):106-18. PubMed ID: 20959361
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
    Chen SM, Liu JL, Wang X, Liang C, Ding J, Meng LH.
    Biochem Pharmacol; 2012 May 01; 83(9):1183-94. PubMed ID: 22305748
    [Abstract] [Full Text] [Related]

  • 10. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J.
    Cancer Res; 2008 Oct 01; 68(19):8022-30. PubMed ID: 18829560
    [Abstract] [Full Text] [Related]

  • 11. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
    Chang KY, Tsai SY, Wu CM, Yen CJ, Chuang BF, Chang JY.
    Clin Cancer Res; 2011 Nov 15; 17(22):7116-26. PubMed ID: 21976531
    [Abstract] [Full Text] [Related]

  • 12. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
    Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R, Modlin IM.
    Cancer; 2011 Sep 15; 117(18):4141-54. PubMed ID: 21387274
    [Abstract] [Full Text] [Related]

  • 13. Suppression of mTOR via Akt-dependent and -independent mechanisms in selenium-treated colon cancer cells: involvement of AMPKalpha1.
    Lee YK, Park SY, Kim YM, Kim DC, Lee WS, Surh YJ, Park OJ.
    Carcinogenesis; 2010 Jun 15; 31(6):1092-9. PubMed ID: 20164123
    [Abstract] [Full Text] [Related]

  • 14. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
    Rocha GZ, Dias MM, Ropelle ER, Osório-Costa F, Rossato FA, Vercesi AE, Saad MJ, Carvalheira JB.
    Clin Cancer Res; 2011 Jun 15; 17(12):3993-4005. PubMed ID: 21543517
    [Abstract] [Full Text] [Related]

  • 15. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.
    Kristof AS, Pacheco-Rodriguez G, Schremmer B, Moss J.
    J Pharmacol Exp Ther; 2005 Sep 15; 314(3):1134-43. PubMed ID: 15923340
    [Abstract] [Full Text] [Related]

  • 16. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 15; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 17. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor.
    Van Aller GS, Carson JD, Tang W, Peng H, Zhao L, Copeland RA, Tummino PJ, Luo L.
    Biochem Biophys Res Commun; 2011 Mar 11; 406(2):194-9. PubMed ID: 21300025
    [Abstract] [Full Text] [Related]

  • 18. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
    D'Angelo ND, Kim TS, Andrews K, Booker SK, Caenepeel S, Chen K, D'Amico D, Freeman D, Jiang J, Liu L, McCarter JD, San Miguel T, Mullady EL, Schrag M, Subramanian R, Tang J, Wahl RC, Wang L, Whittington DA, Wu T, Xi N, Xu Y, Yakowec P, Yang K, Zalameda LP, Zhang N, Hughes P, Norman MH.
    J Med Chem; 2011 Mar 24; 54(6):1789-811. PubMed ID: 21332118
    [Abstract] [Full Text] [Related]

  • 19. PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer.
    Riggio M, Polo ML, Blaustein M, Colman-Lerner A, Lüthy I, Lanari C, Novaro V.
    Carcinogenesis; 2012 Mar 24; 33(3):509-18. PubMed ID: 22180571
    [Abstract] [Full Text] [Related]

  • 20. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.
    Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ.
    Cancer Res; 2005 Sep 15; 65(18):8256-65. PubMed ID: 16166302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 83.